Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including dementia and cardiovascular diseases, although experts warned against seeing ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.